References
- Perry AM, Attar EC. New insights in AML biology from genomic analysis. Semin Hematol. 2014;51(4):282–297. doi:https://doi.org/10.1053/j.seminhematol.2014.08.005.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:https://doi.org/10.1182/blood-2016-03-643544.
- Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol. 2017;179(4):530–542. doi:https://doi.org/10.1111/bjh.14823.
- Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607. doi:https://doi.org/10.1200/JCO.2012.43.7384.
- Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563–3572. doi:https://doi.org/10.1182/blood-2013-01-451781.
- Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011;25(6):1119–1133. doi:https://doi.org/10.1016/j.hoc.2011.09.013.
- Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12. doi:https://doi.org/10.1186/1756-8722-5-12.
- Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511–2523. doi:https://doi.org/10.1007/s00018-019-03084-7.
- Nagase R, Inoue D, Pastore A, et al. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. J Exp Med. 2018;215(6):1729–1747. doi:https://doi.org/10.1084/jem.20171151.
- Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180–193. doi:https://doi.org/10.1016/j.ccr.2012.06.032.
- Asada S, Kitamura T. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. Int J Hematol. 2019;110(2):179–186. doi:https://doi.org/10.1007/s12185-018-2563-7.
- Inoue D, Matsumoto M, Nagase R, et al. Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp Hematol. 2016;44(3):172–176.e171. doi:https://doi.org/10.1016/j.exphem.2015.11.011.
- Yang H, Kurtenbach S, Guo Y, et al. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood. 2018;131(3):328–341. doi:https://doi.org/10.1182/blood-2017-06-789669.
- Hou HA, Tien HF. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Expert Rev Hematol. 2016;9(5):447–469. doi:https://doi.org/10.1586/17474086.2016.1144469.
- Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020;126(4):765–774. doi:https://doi.org/10.1002/cncr.32566.
- Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153–159. doi:https://doi.org/10.1038/nrc3459.
- Kuznetsov JN, Aguero TH, Owens DA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019;5(9):eaax1738 doi:https://doi.org/10.1126/sciadv.aax1738.
- Abdel-Wahab O, Dey A. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia. 2013;27(1):10–15. doi:https://doi.org/10.1038/leu.2012.288.
- Asada S, Goyama S, Inoue D, et al. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018;9(1):2733. doi:https://doi.org/10.1038/s41467-018-05085-9.
- Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137–144. doi:https://doi.org/10.1038/s41569-019-0247-5.
- Olsson L, Zettermark S, Biloglav A, et al. The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes. Br J Haematol. 2016;174(2):292–301. doi:https://doi.org/10.1111/bjh.14056.
- Shiba N, Yoshida K, Shiraishi Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol. 2016;175(3):476–489. doi:https://doi.org/10.1111/bjh.14247.
- Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:https://doi.org/10.1371/journal.pone.0051862.
- Micol JB, Duployez N, Boissel N, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014;124(9):1445–1449. doi:https://doi.org/10.1182/blood-2014-04-571018.
- Lins MM, Mello MJG, Ribeiro RC, De Camargo B, de Fátima Pessoa Militão de Albuque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country. Ann Hematol. 2019;98(6):1403–1411. doi:https://doi.org/10.1007/s00277-019-03661-7.
- Al-Mutlaq HM, Bawazir AA, Jradi H, Al-Dhalaan ZA, Al-Shehri A. Patterns of childhood cancer incidence in Saudi Arabia (1999- 2008). Asian Pac J Cancer Prev. 2015;16(2):431–435. doi:https://doi.org/10.7314/apjcp.2015.16.2.431.
- Radhakrishnan V, Thampy C, Ganesan P, et al. Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India. Indian J Hematol Blood Transfus. 2016;32(3):257–261. doi:https://doi.org/10.1007/s12288-015-0591-5.
- Belgaumi AF, Pathan GQ, Siddiqui K, et al. Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: A population-based analysis. Pediatr Blood Cancer. 2019;66(6):e27684. doi:https://doi.org/10.1002/pbc.27684.
- Jastaniah W, Bayoumy M, Alsultan A, et al. Identifying Prognostic Factors That Influence Outcome of Childhood Acute Myeloid Leukemia in First Relapse in Saudi Arabia: Results of the Multicenter SAPHOS Study. Clin Lymphoma Myeloma Leuk. 2018;18(12):773–780. doi:https://doi.org/10.1016/j.clml.2018.09.001.
- Cagnetta A, Adamia S, Acharya C, et al. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leuk Res. 2014;38(6):649–659. doi:https://doi.org/10.1016/j.leukres.2014.03.006.
- Gambacorta V, Gnani D, Vago L, Di Micco R. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Front Cell Dev Biol. 2019;7:207. doi:https://doi.org/10.3389/fcell.2019.00207.
- Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920–6929. doi:https://doi.org/10.1182/blood-2011-08-368225.
- Kitamura T. ASXL1 mutations gain a function. Blood. 2018;131(3):274–275. doi:https://doi.org/10.1182/blood-2017-12-816595.
- Valerio DG, Katsman-Kuipers JE, Jansen JH, et al. Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia. Haematologica. 2014;99(8):e130–e132. doi:https://doi.org/10.3324/haematol.2013.094565.
- Lonetti A, Pession A, Masetti R. Targeted Therapies for Pediatric AML: Gaps and Perspective. Front Pediatr. 2019;7:463. doi:https://doi.org/10.3389/fped.2019.00463.
- Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32(10):2167–2177. doi:https://doi.org/10.1038/s41375-018-0071-7.
- Gaidzik VI, Paschka P, Späth D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. JCO. 2012;30(12):1350–1357. doi:https://doi.org/10.1200/JCO.2011.39.2886.
- Chen Q, He J, Guo X, et al. TET2 Downregulation Leads to AML Cells Sensitive to Decitabine. Blood. 2015;126(23):3643–3643. doi:https://doi.org/10.1182/blood.V126.23.3643.3643.
- Liang DC, Liu HC, Yang CP, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood. 2013;121(15):2988–2995. doi:https://doi.org/10.1182/blood-2012-06-436782.
- Kumar R, Taylor M, Miao B, et al. BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol. 2015;135(4):1089–1097. doi:https://doi.org/10.1038/jid.2014.528.
- Park CM, Lee JE, Kim JH. BAP1 functions as a tumor promoter in prostate cancer cells through EMT regulation. Genet Mol Biol. 2020;43(2):e20190328. doi:https://doi.org/10.1590/1678-4685-GMB-2019-0328.
- Shahriyari L, Abdel-Rahman M, Cebulla C. BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19. PLoS One. 2019;14(2):e0211507. doi:https://doi.org/10.1371/journal.pone.0211507.
- Jadhav SP, Kumari N, Ng L, et al. circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. Haematologica. 2020;105(7):e343–e348. doi:https://doi.org/10.3324/haematol.2019.225961.